CART2219.1

CART2219.1 · KK Women's and Children's Hospital

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CART2219.1, covering 2023-03-09 to 2023-03-09. Get the full timeline:

Most recent: Clinical Trial Update: Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia [Phase 1, Phase 2]

See pricing